**Supporting Information Table 3.**

**Fecal markers in Crohn’s disease, number of patients and study design.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Reference | Marker | N. of patients | Study Design | |
| Kane 2003 [5] | FL | 104 | Observational | Prospective |
| Walker 2007 [6] | FL | 79 | Observational | Prospective |
| Schoepffer 2007 [7] | FL | 24 | Observational | Prospective |
| Dai 2007 [8] | FL | 18 | Observational | Prospective |
| Jones 2008 [11] | FL | 165 | Observational | Prospective |
| Sipponen 2008 [39] | FL | 77 | Observational | Prospective |
| Vieira 2009 [9] | FL | 38 | Observational | Prospective |
| Pfefferkorn 2010 [38] | FL | 54 | Observational | Prospective |
| Karczewski 2015 [10] | FL | 55 | Observational | Prospective |
| De Jong 2006 [12] | S100A12 | 22 | Observational | Prospective |
| Kaiser 2007 [14] | S100A12 | 32 | Observational | Prospective |
| Sidler 2008 [13] | S100A12 | 30 | Observational | Prospective |
| Vitali 2011 [81] | HMGB1 | 19 | Observational | - |
| Husain 2013 [15] | Neopterin | 70 | Observational | Prospective |
| Nancey 2013 [16] | Neopterin | 78 | Observational | Prospective |
| Adeyemi 1992 [17] | PMN-e | 20 | Observational | - |
| Andus 1993 [20] | PMN-e | 70 | Observational | Prospective |
| Saitoh 1995 [18] | PMN-e | 26 | Observational | - |
| Sugi 1996 [19] | PMN-e | 34 | Observational | Prospective |
| Mooiweer 2014 [48] | F-Hb | 83 | Observational | Prospective |
| Meyers 1985 [33] | AAT | 24 | Observational | Prospective |
| Herzog 1996 [35] | AAT | 42 | Observational | Prospective |
| Becker 1999 [34] | AAT | 9 | Observational | Prospective |
| Thorsvik 2017 [21] | NGAL | 30 | Observational | Prospective |
| Buisson 2016 [22] | CHI3L1 | 54 | Observational | Prospective |
| Farkas 2015 [82] | MMP-9 | 50 | Observational | Prospective |
| Czub 2007 [29] | M2-PK | 32 | Observational | Prospective |
| Czub 2014 [83] | M2-PK | 46 | Observational | Prospective |
| Chung-Faye 2007 [24] | M2-PK | 31 | Observational | Prospective |
| Day 2012 [36] | M2-PK | 17 | Observational | - |
| Roszak 2015 [30] | M2-PK | 47 | Observational | Prospective |
| Peterson 2002 [25] | EPX | 7 | Observational | Prospective |
| Saitoh 1999 [26] | EPX, ECP | 37 | Observational | Prospective |
| Van der Sluys Veer 1998 [23] | Lys | 112 | Observational | Prospective |
| Kolho 2014 [37] | MMP-9, HBD-2 | 68 | Observational | Prospective |
| D’Inca 2007 [44] | FL | 23 | Observational | Prospective |
| Langhorst 2008 [79] | FL | 43 | Observational | Prospective |
| Sipponen 2008 [41] | FL | 61 | Observational | Prospective |
| Sipponen 2008 [56] | FL | 15 | Observational | Prospective |
| Klimczak 2015 [42] | FL | 101 | Observational | Prospective |
| Bar-Gil Shitrit 2017 [52] | FL | 23 | Observational | Prospective |
| Aggarwal 2017 [43] | FL, S100A12 | 43 | Observational | Prospective |
| Sipponen 2012 [53] | S100A12 | 84 | Observational | Prospective |
| Palone 2014 [45] | HMGB1 | 28 | Observational | Prospective |
| Palone 2016 [46] | HMGB1 | 57 | Observational | Prospective |
| Inokuchi 2016 [47] | F-Hb | 71 | Observational | Prospective |
| Cellier 1994 [31] | AAT | 95 | Observational | Prospective |
| Moran 1995 [85] | AAT | 7 | Observational | Prospective |
| Aomatsu 2011 [32] | CHI3L1 | 87 | Observational | Prospective |
| Vazquez Moròn 2017 [27] | M2-PK | 71 | Observational | Prospective |
| Sidhu 2010 [51] | FL | 17 | Observational | Prospective |
| Buderus 2004 [55] | FL | 5 | Observational | Prospective |
| Sipponen 2010 [57] | FL | 19 | Observational | Prospective |
| Lykowska-Szuber 2016 [58] | FL | 35 | Observational | Prospective |
| Nogueira 2013 [86] | FL | 17 | Observational | Prospective |
| Boschetti 2015 [59] | S100A12 | 32 | Observational | Prospective |
| Wagner 2008 [60] | MPO, EPX | 10 | Observational | Prospective |
| Gisbert 2009 [61] | FL | 89 | Observational | Prospective |
| Däbritz 2013 [62] | S100A12 | 61 | Observational | Prospective |
| Biancone 2003 [63] | AAT | 26 | Observational | Prospective |
| Scarpa 2007 [64] | FL | 63 | Observational | Prospective |
| Lamb 2009 [65] | FL | 104 | Observational | Prospective |
| Yamamoto 2013 [67] | FL | 20 | Observational | Prospective |
| Ruffolo 2010 [66] | FL | 36 | Observational | Prospective |
| Wright 2016 [70] | FL, S100A12 | 135 | Trial | Prospective |
| Lopes 2016 [68] | FL | 99 | Observational | Prospective |
| Lopes 2017 [69] | FL | 58 | Observational | Prospective |
| Boirivant 1991 [71] | AAT | 11 | Observational | Prospective |
| Buisson 2018 [28] | NGAL | 54 | Observational | Prospective |
| Rubio 2019 [84] | FL | 131 | Observational | Retrospective |

FL: faecal lactoferrin; HMGB1: high mobility group box 1; PMN-e: polymorphonuclear neutrophil elastase; F-Hb: faecal haemoglobin; AAT: alpha1-antitrypsin; Lys: lysozyme; HBD2: human beta-defensin-2; NGAL: neutrophil gelatinase-associated lipocalin; MMP9: matrix metalloproteinase 9; CHI3L1: chitinase 3-like-1; M2-PK: M2-pyruvate kinase; MPO: myeloperoxidase; ECP: eosinophil cationic protein; EPX: eosinophil protein X.